Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;114(1):79-88.
doi: 10.1111/ejh.14305. Epub 2024 Sep 19.

Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission

Normann Steiner  1   2 , Radwan Massoud  1 , Johanna Richter  1 , Tetiana Perekhrestenko  1   3 , Nico Gagelmann  1 , Christian Niederwieser  1 , Kristin Rathje  1 , Iryna Lastovytska  1 , Mathias Schäfersküpper  1 , Silke Heidenreich  1 , Ina Rudolph  1 , Gaby Zeck  1 , Dietlinde Janson  1 , Christine Wolschke  1 , Francis Ayuketang Ayuk  1 , Evgeny Klyuchnikov  1 , Nicolaus Kröger  1
Affiliations

Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission

Normann Steiner et al. Eur J Haematol. 2025 Jan.

Abstract

Background: The optimal TBI dose for ALL patients undergoing allogeneic SCT is still not clearly defined.

Methods: Single-center retrospective analysis of high-risk ALL patients in CR1 treated with 8 Gy (n = 22) or 12 Gy (n = 50) TBI in combination with fludarabine and PTCy. Median patient age in the 8 Gy TBI cohort was 63 (37-79) and 37 (18-56) in the 12 Gy TBI cohort and median follow-up time was 21 months (range 1-92).

Results: OS and LFS at 2 years after 8 Gy were 65% and 55% versus 74% and 74% after 12 Gy (p = 0.3 and p = 0.2, respectively). CIR and NRM at 2 years were 27% and 14% after 8 Gy versus 4% and 20% after 12 Gy (p = 0.004 and p = 0.4, respectively). MRD-positive (+) patients (n = 26) receiving 12 Gy (n = 19) showed better OS (p = 0.01), LFS (p = 0.009), GRFS, lower CIR (p = 0.02), and similar NRM than did MRD+ patients receiving 8 Gy (n = 7). MRD-negative (-) patients (n = 38) receiving 12 Gy (n = 27) had similar OS, LFS, GRFS, lower CIR, and higher NRM (p = 0.04) than did MRD- patients receiving 8 Gy (n = 11).

Conclusion: Our study demonstrates that 8 Gy TBI in comparison to 12 Gy TBI results in low NRM but a high relapse rate with similar OS, LFS, and GRFS. In MRD+ high-risk ALL patients, allogeneic SCT with 12 Gy TBI leads to improved OS, LFS, GRFS, and a low relapse rate. Prospective studies comparing the different treatment regimens with larger MRD patient cohorts are needed to confirm this data.

Keywords: 12 Gy TBI; 8 Gy TBI; PTCy; acute lymphoblastic leukemia; allogeneic stem cell transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Overall survival after alloSCT for MRD‐positive (+) and negative (−) ALL patients treated with 8 Gy TBI or 12 Gy TBI.
FIGURE 2
FIGURE 2
Leukemia‐free survival after alloSCT for MRD‐positive (+) and negative (−) ALL patients treated with 8 Gy TBI or 12 Gy TBI.
FIGURE 3
FIGURE 3
Non‐relapse mortality after alloSCT for MRD‐positive (+) and negative (−) ALL patients treated with 8 Gy TBI or 12 Gy TBI.
FIGURE 4
FIGURE 4
Cumulative incidence of relapse after alloSCT for MRD‐positive (+) and negative (−) ALL patients treated with 8 Gy TBI or 12 Gy TBI.
See this image and copyright information in PMC

References

    1. Kantarjian H., Thomas D., O'Brien S., et al., “Long‐Term Follow‐Up Results of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper‐CVAD), a Dose‐Intensive Regimen, in Adult Acute Lymphocytic Leukemia,” Cancer 101, no. 12 (2004): 2788–2801. - PubMed
    1. Sive J. I., Buck G., Fielding A., et al., “Outcomes in Older Adults With Acute Lymphoblastic Leukaemia (ALL): Results From the International MRC UKALL XII/ECOG2993 Trial,” British Journal of Haematology 157, no. 4 (2012): 463–471. - PMC - PubMed
    1. Gökbuget N., Kneba M., Raff T., et al., “Adult Patients With Acute Lymphoblastic Leukemia and Molecular Failure Display a Poor Prognosis and Are Candidates for Stem Cell Transplantation and Targeted Therapies,” Blood 120, no. 9 (2012): 1868–1876. - PubMed
    1. Champlin R., Khouri I., Shimoni A., et al., “Harnessing Graft‐Versus‐Malignancy: Non‐Myeloablative Preparative Regimens for Allogeneic Haematopoietic Transplantation, an Evolving Strategy for Adoptive Immunotherapy,” British Journal of Haematology 111, no. 1 (2000): 18–29. - PubMed
    1. Giebel S., Labopin M., Socié G., et al., “Improving Results of Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia in First Complete Remission: An Analysis From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation,” Haematologica 102, no. 1 (2017): 139–149. - PMC - PubMed

MeSH terms

LinkOut - more resources